Historical and contemporary management of infantile hemangiomas: a single-center experience.

Objective: This study explores the 22-year evolution of Infantile Hemangiomas (IHs) treatment strategies at a single-center hospital, aiming to establish an individualized IHs management protocol. Methods: Retrospective review of IHs infants 2000-2022 at the Department of Plastic Surgery, Jiangxi Provincial Children's Hospital. Results: In our study of 27,513 IHs cases, 72.2% were female, with the median age at first hospital visit being 25 days. The majority of cases had localized and superficial lesions primarily on the head, face, and neck (67.5%). Ulceration rates fell from 21.1% to 12.6% with the introduction of propranolol. Management strategies have shifted over time, with the proportion of cases undergoing expectant management dropping from 32.9% to 12.4%. Since 2008, 26.1% of patients were treated with oral propranolol, largely replacing corticosteroids. Topical ß-blockers have been used in 12.1% of cases, leading to a reduction in local injection therapy from 20.8% to 13.2%. Laser therapy, introduced in 2016, has been used in 13.8% of cases, while surgical excision has dropped from 25.0% to 8.5% due to alternative treatment options. Combination therapy was used in 8.8% of cases post-2015, indicating a rising trend. Drawing from the evolution of IHs management strategies, an individualized protocol for the management of IHs was successfully established. Conclusion: Treatment for IHs has evolved over recent decades, with less invasive medical interventions increasingly replacing more invasive methods. Furthermore, a personalized treatment protocol established in this study could boost the cure rate of IHs while minimizing potential side effects and complications.

6-Nitrodopamine Is the Most Potent Endogenous Positive Inotropic Agent in the Isolated Rat Heart.

BACKGROUND: 6-nitrodopamine released from rat isolated atria exerts positive chronotropic action, being more potent than noradrenaline, adrenaline, and dopamine. Here, we determined whether 6-nitrodopamine is released from rat isolated ventricles (RIV) and modulates heart inotropism. METHODS: Catecholamines released from RIV were quantified by LC-MS/MS and their effects on heart inotropism were evaluated by measuring left ventricular developed pressure (LVDP) in Langendorff's preparation. RESULTS: 6-nitrodopamine was the major released catecholamine from RIV. Incubation with L-NAME (100 µM), but not with tetrodotoxin (1 µM), caused a significant reduction in 6-nitrodopamine basal release. 6-nitrodopamine release was significantly reduced in ventricles obtained from L-NAME chronically treated animals. 6-nitrodopamine (0.01 pmol) caused significant increases in LVDP and dP/dtmax, whereas dopamine and noradrenaline required 10 pmol, and adrenaline required 100 pmol, to induce similar increases in LVDP and dP/dtmax. The infusion of atenolol (10 nM) reduced basal LVDP and blocked the increases in LVDP induced by 6-ND (0.01 pmol), without affecting the increases in LVDP induced by 10 nmol of dopamine and noradrenaline and that induced by adrenaline (100 nmol). CONCLUSIONS: 6-nitrodopamine is the major catecholamine released from rat isolated ventricles. It is 1000 times more potent than dopamine and noradrenaline and is selectively blocked by atenolol, indicating that 6-ND is a main regulator of heart inotropism.

Comparison of Medical Treatments According to the Characteristics of Idiopathic Premature Ventricular Contractions: Beta-blockers or Calcium Channel Blockers?

Objective: Premature ventricular contractions (PVCs) are a common arrhythmic condition. The first approach in patients with symptomatic and frequent PVC is medical treatment, primarily beta-blockers (BB) or calcium channel blockers (CCB), but it is still unclear which of the two should be chosen. This study investigated which drug treatment would be beneficial according to patient and electrocardiography (ECG) characteristics in patients with idiopathic PVC. Methods: We retrospectively analyzed 156 patients with PVC who came to the cardiology outpatient clinic. Seventy-one patients were responsive to BB, and 85 were responsive to CCB. Their demographic and ECG characteristics were compared. Results: The male ratio was higher (p<0.001), and the left ventricular ejection fraction was lower in BB responders than in CCB responders (p<0.001). Although the mean heart rate was higher in BB responders (p<0.001), the initial PVC burden was lower in BB responders than in CCB responders (p<0.001). The PVC QRS duration was longer in BB responders than in CCB responders (p<0.001). Similarly, the coupling interval variability was higher in BB responders (p=0.006). Conclusions: The evaluation of clinical and ECG parameters in patients with frequent idiopathic PVCs may determine whether BBs or CCBs should be chosen as initial treatment. Further prospective studies are needed to verify our findings and establish their clinical applicability.

The Role and Efficacy of Coenzyme Q10 in the Management of Erectile Dysfunction in a Hypertensive Male: An Interventional Study.

Introduction Erectile dysfunction (ED) is a prevalent medical condition that affects millions of men globally. A number of pharmacological and complementary options are used in the management of ED, including Coenzyme Q10 (CoQ10). Oxidative stress has been linked to the progression of ED, and Co Q10 protects against oxidative damages and improves erectile function as well as the activity of antioxidant enzymes. This study aimed to determine the efficacy of CoQ10 in the treatment of erectile dysfunction in hypertensive males. Method An open-labeled parallel arm interventional study was conducted in the cardiology unit of Hayatabad Medical Complex Hospital, Peshawar, Pakistan, from March 2020 to March 2021. Hypertensive male patients (n = 230) were randomly allocated to either receiving 200-gram CoQ10 daily along with their current antihypertensive therapy (n=104) or anti-hypertensive treatment only (n=105). The patient's erectile function was assessed at baseline and three months using the International Index of Erectile Function Test (IIEF-5) during the study period. Result Of the total 230, 209 (90.87%) patients were included in the final analysis. There were no significant differences in demographics, history of illness, co-morbid conditions, and current medication of both groups. After three months, 21 (20.1%) participants scored more than 17 in the IIEF-5 and no longer had ED. Overall, no significant difference was found in the mean IIEF-5 score between the study group and control group (14.41 ± 4.49 Vs. 15.61 ± 4.82; p=0.06). However, in subgroup analysis, significant improvement in the study group was seen in participants with mild ED (p=0.03). Conclusion With the demonstration of its efficacy in hypertensive patients with mild ED, co-enzyme Q10 supplementation can be proposed as a potential candidate in patients with long-term hypertension and can play a role in erectile dysfunction.

The role of topical timolol in wound healing and the treatment of vascular lesions: A narrative review.

Beta-2 adrenergic receptors are the only subgroup of beta-adrenergic receptors expressed in the membrane of large cells, including skin keratinocytes, fibroblasts, and melanocytes. Alterations in the function or concentration of ß2 adrenoreceptors related to keratinocytes are associated with some skin conditions. Some findings suggest the role of ß2 adrenoreceptors in maintaining the function and integrity of the epidermis. Beta-receptor antagonists can be systemically and topically effective in healing hemangioma, paronychia, vasculitis ulcer, tufted angioma, acute and chronic wounds. Most studies with a strong design on this subject deal with the systemic form, but recently, numerous case and group reports and smaller studies have focused on topical forms, especially topical timolol. The present comprehensive review study surveys the role of topical timolol in acute and chronic wound healing in the field of dermatology.

Differences in brand versus generic esmolol in the treatment of perioperative supraventricular tachycardia and hypertension: A pilot study.

BACKGROUND: Once a patent expires, generic analogue drugs are alternatives to brand name drugs. Because bioequivalence/biodistribution problems have been reported for many generic analogue drugs, we prospectively evaluated 31 patients to reveal the differences in the doses used and the efficacy and adverse events of two different intravenous esmolol formulations. METHODS: This was a prospective observational pilot study. Our aim was to reveal the possible differences in the required doses between two different formulations (brand name drug vs generic analogue drug) of intravenous esmolol in beats per minute, systolic blood pressure, diastolic blood pressure and mean arterial pressure in intra- and postoperative patients with supraventricular tachycardia and hypertension. The patients were categorised into two groups according to the medication they received (brand name drug or generic analogue drug). RESULTS: Esmolol was given to 31 patients (16 generic analogue drug and 15 brand name drug). Although there was a statistically significant difference in bolus (mg/kg) and continued (mg/kg/h) drug dose used (brand name drug/generic analogue drug, mean (standard deviation), 0.3 (0.1) vs 0.38 (0.1), p = 0.03 for bolus dose, and 0.22 (0.09) vs 0.29 (0.08) for continued dose at 10 min (p = 0.03), 0.19 (0.06) vs 0.24 (0.05) at 20 min (p = 0.01) and 0.14 (0.05) vs 0.18 (0.05) at 30 min (p = 0.02)), there were no time-related statistical significant differences in the reduction rates of the two drugs (p = 0.47). There were no time-related statistically significant differences between the two groups in systolic blood pressure, diastolic blood pressure, mean arterial pressure and beats per minute, nor in their adverse events. CONCLUSION: In this pilot study, smaller doses were given for controlling the patient's haemodynamics when a brand name drug was used. Because there were no significant time-related differences in the reduction rates of the two drugs nor in any haemodynamic differences between the two groups, optimal titration of the drug used could effectively control the patient's haemodynamics. The adverse events were also similar in both groups.

Meta-analysis of the benefit of beta-blockers for the reduction of isolated atrial fibrillation incidence after cardiac surgery.

Objectives: Postoperative atrial fibrillation (POAF) is a common problem of cardiac surgery. Beta-blockers are recognized as effective prophylactic agents available for POAF management. To better understand its effect on isolated atrial fibrillation after cardiac surgery, a meta-analysis was conducted. Methods: Randomized controlled trials (RCTs) were searched and filtered by comparing the efficacy of beta-blockers and control users in isolated POAF for cardiac surgery. Seventeen RCTs were identified and analyzed by typical meta-analysis methods. The search was performed from inception to May 31, 2020. Subgroup analyses were conducted for type of surgery and beta-blocker, starting time and route of administration of beta-blocker, and dosage of intravenous landiolol hydrochloride. Results: Beta-blockers were effective in reducing isolated POAF risk (risk ratio [RR], 0.52 [0.41, 0.66], P = .31, I2 = 12%). In subgroup analyses, beta-blocker administration during postoperative period (RR, 0.43 [0.29, 0.62], P = .84, I2 = 0%) and on-pump coronary artery bypass graft (RR, 0.34 [0.04, 3.15], P = .56, I2 = 0%) had lowest risk of isolated POAF incidence. Intravenous landiolol hydrochloride at 2 µg/kg/min also had low risk of isolated POAF occurrence. Conclusions: Beta-blocker treatment helps to reduce isolated atrial fibrillation incidence after cardiac surgery. Our subgroup analyses also reveal postoperative beta-blocker administration after on-pump coronary artery bypass graft surgery is most effective in reducing isolated POAF risk. Intravenous landiolol hydrochloride at a dosage of 2 µg/kg/min has also displayed favorable results. Further trials may be required to explore these factors.

Changes in transient elastography in early cirrhotic patients after receiving nonselective B-blocker for primary variceal bleeding prophylaxis: Three-month follow up.

BACKGROUND AND AIM: A nonselective B-blocker (NSBB) is recommended for primary prophylaxis of variceal bleeding. The impact of treatment with NSBB on modulating transient elastography (TE) has not been reported. The aim of the study is to investigate the effect of NSBB treatment on TE in early cirrhotic patients. METHODS: In this prospective study, we enrolled all early cirrhotic patients who underwent esophagogastroduodenoscopy (EGD) and showed small esophageal varices (EV) at our institute for a period of 1 year. The TE and heart rate (HR) of all participants were measured before and 3 months after receiving NSBB. RESULTS: Thirty-nine patients receiving propanolol for 3 months were analyzed. There were 16 patients in the HR responder group (41%) and 23 patients in the HR nonresponder group (59%). The reduction of TE was preferably found in the HR responder group compared with the HR nonresponder group, in which mean changes in TE were -5.6 and -0.7 kPa, respectively (P = 0.23). In addition, we categorized the patients using their TE responses. Twenty-five patients (64.1%) showed reduced TE during the follow-up period, in which the mean TE value change was -2.94 kPa. Using correlation analysis, TE and HR responses were insignificantly correlated (r = 0.23, P = 0.15). CONCLUSION: The NSBB administered for 3 months mainly improved TE value in early cirrhotic patients even though the changes of HR and TE did not correlate. Further study is needed to confirm whether the monitoring of TE change may be a better predictor for pharmacological response than the HR response.

Effect of chronic pretreatment with beta-blockers on no-reflow phenomenon in diabetic patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

BACKGROUND: No-reflow is an important factor as it predicts a poor outcome in patients undergoing primary angioplasty. In comparison with patients attaining TIMI 3 flow, patients with no-reflow have an increased incidence of ventricular arrhythmias, early congestive cardiac failure, cardiac rupture and cardiac death. As such, it is of paramount importance to consider strategies to prevent the occurrence of no-reflow phenomenon. Previous evidence suggests that Beta (ß) blockers have multiple favorable effects on the vascular system not directly related to their effect on blood pressure. However, there are insufficient data regarding the effects of prior Beta blocker use on coronary blood flow after primary PCI in patients with AMI. AIM: The aim of this study was to test the hypothesis that Beta blocker treatment before admission would have beneficial effects on the development of the no-reflow phenomenon after acute myocardial infarction. METHODS AND RESULTS: The study included 107 diabetic patients who had presented with acute STEMI within 12 h from the onset of chest pain. All of them have undergone primary angioplasty at Ain Shams University hospitals or National Heart institute. The incidence of no-reflow phenomenon was 21%. No-reflow phenomenon was significantly lower in patients on chronic B-blocker therapy (12% vs. 28%; P = 0.04). The heart rate was significantly lower in the normal reflow group than in the no-reflow group (P = 0.03). The study also showed that B-blocker pretreatment is an independent protective predictor for the no-reflow phenomenon (P = 0.045). CONCLUSION: Chronic pre-treatment with B-blocker in diabetic patients presenting with STEMI, is associated with lower rate of occurrence of no-reflow phenomenon after primary PCI.

Periprocedural Nebivolol for the Prevention of Contrast-Induced Acute Kidney Injury: A Systematic Review and Meta-analysis.

BACKGROUND: Nebivolol provides a protective effect on contrast-induced acute kidney injury (CIAKI) in animal models. However, the reports on the efficacy of nebivolol for the prevention of CIAKI in human remain unclear. AIMS: The objective of this meta-analysis was to assess the effect of nebivolol for the prevention of CIAKI. MATERIALS AND METHODS: Comprehensive literature searches were performed using MEDLINE, EMBASE, and Cochrane Database from inception through February 2015. Studies that reported relative risks, odd ratios, or hazard ratios comparing the risk of CIAKI in patients who received nebivolol versus those who did not were included. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method. RESULTS: Four studies (2 randomized controlled trials and 2 cohort studies) with 543 patients were included in our analysis to assess the risk of CIAKI and the use of nebivolol. Patients in the nebivolol group had an overall lower incidence of CIAKI (14.4%) compared to the control group (18.4%). The pooled RR of CIAKI in patients receiving nebivolol was 0.66 (95% CI: 0.38-1.15, I (2) = 0). When meta-analysis was limited only to randomized control trials (RCTs), the pooled RR of CIAKI in patients receiving nebivolol was 0.79 (95% CI: 0.35-1.79, I (2) = 0%). CONCLUSIONS: Despite no statistical significance, there was a trend toward reduced CIAKI risk in patients receiving nebivolol. The findings of our meta-analysis suggest the need of a large RCT with very careful attention to the balance of benefits and harms.

Control ambulatorio de la presión arterial en hipertensos sistólicos con cardiopatía isquémica asociada / Ambulatory control of arterial systolic pressure in hypertensive patients presenting with associated ischemic heart disease

Cuando la cardiopatía isquémica coexiste con la hipertensión arterial, el tratamiento de esta se torna una tarea compleja. El objetivo de este trabajo fue evaluar el efecto sobre el control ambulatorio de la presión arterial (en una cohorte de hipertensos sistólicos mayores de 50 años con cardiopatía isquémica asociada) de una estrategia de tratamiento antihipertensivo basada en un betabloqueador (atenolol), un diurético y un inhibidor de la enzima convertidora de angiotensina. Se incluyeron 126 pacientes (hipertensos no controlados mayores de 50 años con cardiopatía isquémica estable crónica que fueron evaluados al inicio y a las 6, 24 y 52 sem. A las 6 sem estaban controlados el 52,38 por ciento de los pacientes, a los 6 meses 54,76 por ciento y al año el 71,42 por ciento. Los resultados indican que el tratamiento fue efectivo para controlar la presión arterial y reducir las crisis de angina de pecho en hipertensos sistólicos. Para lograr esto, la mayoría de los pacientes necesitó 2 ó 3 medicamentos, lo que indica que esta cohorte de pacientes hipertensos sistólicos, en su mayoría de la tercera edad y con una cardiopatía isquémica estable crónica asociada, necesitan una terapéutica adecuada, con un seguimiento frecuente

When ischemic heart disease is associated with arterial hypertension, treatment becomes a complex task. A group of 126 non-controlled patients with isolated systolic hypertension aged over 50 with associated ischemic heart disease was studied to assess the effect of an antihypertensive treatment strategy based on the combination of a b-blocker (Atenolol), a diuretic, and an angiotensin-converting enzyme inhibitor (ACEI) on the ambulatory control of arterial pressure. All patients were assessed at onset and 6, 24 and 52 weeks later. The percentage of patients achieving blood pressure control was 52.38 percent; 54.76 percent and 71.42 percent at 6, 24 and 52 weeks respectively. The results showed that treatment was effective to control the arterial pressure and to reduce the angina episodes in the systolic hypertensive ones. To achieve it, most of patients needed two or three drugs indicating that this group of hypertensive and systolic patients in the main of third age and with an associated chronic stable ischemic heart disease needs an appropriate therapy with a frequent follow-up

Control ambulatorio de la presión arterial en hipertensos sistólicos con cardiopatía isquémica asociada / Ambulatory control of arterial systolic pressure in hypertensive patients presenting with associated ischemic heart disease

Cuando la cardiopatía isquémica coexiste con la hipertensión arterial, el tratamiento de esta se torna una tarea compleja. El objetivo de este trabajo fue evaluar el efecto sobre el control ambulatorio de la presión arterial (en una cohorte de hipertensos sistólicos mayores de 50 años con cardiopatía isquémica asociada) de una estrategia de tratamiento antihipertensivo basada en un betabloqueador (atenolol), un diurético y un inhibidor de la enzima convertidora de angiotensina. Se incluyeron 126 pacientes (hipertensos no controlados mayores de 50 años con cardiopatía isquémica estable crónica que fueron evaluados al inicio y a las 6, 24 y 52 sem. A las 6 sem estaban controlados el 52,38 por ciento de los pacientes, a los 6 meses 54,76 por ciento y al año el 71,42 por ciento. Los resultados indican que el tratamiento fue efectivo para controlar la presión arterial y reducir las crisis de angina de pecho en hipertensos sistólicos. Para lograr esto, la mayoría de los pacientes necesitó 2 ó 3 medicamentos, lo que indica que esta cohorte de pacientes hipertensos sistólicos, en su mayoría de la tercera edad y con una cardiopatía isquémica estable crónica asociada, necesitan una terapéutica adecuada, con un seguimiento frecuente(AU)

When ischemic heart disease is associated with arterial hypertension, treatment becomes a complex task. A group of 126 non-controlled patients with isolated systolic hypertension aged over 50 with associated ischemic heart disease was studied to assess the effect of an antihypertensive treatment strategy based on the combination of a b-blocker (Atenolol), a diuretic, and an angiotensin-converting enzyme inhibitor (ACEI) on the ambulatory control of arterial pressure. All patients were assessed at onset and 6, 24 and 52 weeks later. The percentage of patients achieving blood pressure control was 52.38 percent; 54.76 percent and 71.42 percent at 6, 24 and 52 weeks respectively. The results showed that treatment was effective to control the arterial pressure and to reduce the angina episodes in the systolic hypertensive ones. To achieve it, most of patients needed two or three drugs indicating that this group of hypertensive and systolic patients in the main of third age and with an associated chronic stable ischemic heart disease needs an appropriate therapy with a frequent follow-up(AU)

Control ambulatorio de la presión arterial en hipertensos sistólicos con cardiopatía isquémica asociada / Ambulatory control of arterial systolic pressure in hypertensive patients presenting with associated ischemic heart disease

Cuando la cardiopatía isquémica coexiste con la hipertensión arterial, el tratamiento de esta se torna una tarea compleja. El objetivo de este trabajo fue evaluar el efecto sobre el control ambulatorio de la presión arterial (en una cohorte de hipertensos sistólicos mayores de 50 años con cardiopatía isquémica asociada) de una estrategia de tratamiento antihipertensivo basada en un betabloqueador (atenolol), un diurético y un inhibidor de la enzima convertidora de angiotensina. Se incluyeron 126 pacientes (hipertensos no controlados mayores de 50 años con cardiopatía isquémica estable crónica que fueron evaluados al inicio y a las 6, 24 y 52 sem. A las 6 sem estaban controlados el 52,38 por ciento de los pacientes, a los 6 meses 54,76 por ciento y al año el 71,42 por ciento. Los resultados indican que el tratamiento fue efectivo para controlar la presión arterial y reducir las crisis de angina de pecho en hipertensos sistólicos. Para lograr esto, la mayoría de los pacientes necesitó 2 ó 3 medicamentos, lo que indica que esta cohorte de pacientes hipertensos sistólicos, en su mayoría de la tercera edad y con una cardiopatía isquémica estable crónica asociada, necesitan una terapéutica adecuada, con un seguimiento frecuente(AU)

When ischemic heart disease is associated with arterial hypertension, treatment becomes a complex task. A group of 126 non-controlled patients with isolated systolic hypertension aged over 50 with associated ischemic heart disease was studied to assess the effect of an antihypertensive treatment strategy based on the combination of a b-blocker (Atenolol), a diuretic, and an angiotensin-converting enzyme inhibitor (ACEI) on the ambulatory control of arterial pressure. All patients were assessed at onset and 6, 24 and 52 weeks later. The percentage of patients achieving blood pressure control was 52.38 percent; 54.76 percent and 71.42 percent at 6, 24 and 52 weeks respectively. The results showed that treatment was effective to control the arterial pressure and to reduce the angina episodes in the systolic hypertensive ones. To achieve it, most of patients needed two or three drugs indicating that this group of hypertensive and systolic patients in the main of third age and with an associated chronic stable ischemic heart disease needs an appropriate therapy with a frequent follow-up(AU)